vs
COLLEGIUM PHARMACEUTICAL, INC（COLL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是COLLEGIUM PHARMACEUTICAL, INC的1.0倍（$207.3M vs $205.4M），COLLEGIUM PHARMACEUTICAL, INC净利率更高（8.3% vs -62.0%，领先70.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 12.9%），COLLEGIUM PHARMACEUTICAL, INC自由现金流更多（$122.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 19.1%）
Collegium制药是一家专科制药企业，专注于研发和商业化具备滥用威慑特性的创新疼痛管理疗法，主要面向美国市场，推出适用于慢性疼痛患者的缓释镇痛产品，服务覆盖基层及专科医疗领域的医护人员。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
COLL vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.4M | $207.3M |
| 净利润 | $17.0M | $-128.6M |
| 毛利率 | 62.5% | — |
| 营业利润率 | 29.6% | -54.7% |
| 净利率 | 8.3% | -62.0% |
| 营收同比 | 12.9% | 25.9% |
| 净利润同比 | 35.3% | 3.5% |
| 每股收益（稀释后） | $0.48 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $205.4M | $207.3M | ||
| Q3 25 | $209.4M | $159.9M | ||
| Q2 25 | $188.0M | $166.5M | ||
| Q1 25 | $177.8M | $139.3M | ||
| Q4 24 | $181.9M | $164.6M | ||
| Q3 24 | $159.3M | $139.5M | ||
| Q2 24 | $145.3M | $147.0M | ||
| Q1 24 | $144.9M | $108.8M |
| Q4 25 | $17.0M | $-128.6M | ||
| Q3 25 | $31.5M | $-180.4M | ||
| Q2 25 | $12.0M | $-115.0M | ||
| Q1 25 | $2.4M | $-151.1M | ||
| Q4 24 | $12.5M | $-133.2M | ||
| Q3 24 | $9.3M | $-133.5M | ||
| Q2 24 | $19.6M | $-131.6M | ||
| Q1 24 | $27.7M | $-170.7M |
| Q4 25 | 62.5% | — | ||
| Q3 25 | 61.7% | — | ||
| Q2 25 | 57.7% | — | ||
| Q1 25 | 54.8% | — | ||
| Q4 24 | 54.0% | — | ||
| Q3 24 | 60.8% | — | ||
| Q2 24 | 62.5% | — | ||
| Q1 24 | 63.1% | — |
| Q4 25 | 29.6% | -54.7% | ||
| Q3 25 | 29.7% | -106.9% | ||
| Q2 25 | 18.7% | -64.8% | ||
| Q1 25 | 12.2% | -102.6% | ||
| Q4 24 | 20.9% | -74.3% | ||
| Q3 24 | 21.9% | -94.6% | ||
| Q2 24 | 32.7% | -79.1% | ||
| Q1 24 | 34.1% | -151.9% |
| Q4 25 | 8.3% | -62.0% | ||
| Q3 25 | 15.0% | -112.8% | ||
| Q2 25 | 6.4% | -69.0% | ||
| Q1 25 | 1.4% | -108.5% | ||
| Q4 24 | 6.9% | -80.9% | ||
| Q3 24 | 5.9% | -95.7% | ||
| Q2 24 | 13.5% | -89.5% | ||
| Q1 24 | 19.1% | -156.8% |
| Q4 25 | $0.48 | $-1.28 | ||
| Q3 25 | $0.84 | $-1.81 | ||
| Q2 25 | $0.34 | $-1.17 | ||
| Q1 25 | $0.07 | $-1.57 | ||
| Q4 24 | $0.36 | $-1.34 | ||
| Q3 24 | $0.27 | $-1.40 | ||
| Q2 24 | $0.52 | $-1.52 | ||
| Q1 24 | $0.71 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $386.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $301.7M | $-80.0M |
| 总资产 | $1.7B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $386.7M | $421.0M | ||
| Q3 25 | $285.9M | $202.5M | ||
| Q2 25 | $222.2M | $176.3M | ||
| Q1 25 | $197.8M | $127.1M | ||
| Q4 24 | $162.8M | $174.0M | ||
| Q3 24 | $120.0M | $150.6M | ||
| Q2 24 | $271.6M | $480.7M | ||
| Q1 24 | $318.0M | $112.3M |
| Q4 25 | $301.7M | $-80.0M | ||
| Q3 25 | $274.8M | $9.2M | ||
| Q2 25 | $232.2M | $151.3M | ||
| Q1 25 | $234.4M | $144.2M | ||
| Q4 24 | $228.8M | $255.0M | ||
| Q3 24 | $234.3M | $346.8M | ||
| Q2 24 | $216.6M | $432.4M | ||
| Q1 24 | $222.2M | $140.3M |
| Q4 25 | $1.7B | $1.5B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.5B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $123.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $122.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 59.6% | -48.6% |
| 资本支出强度资本支出/营收 | 0.3% | 0.5% |
| 现金转化率经营现金流/净利润 | 7.25× | — |
| 过去12个月自由现金流最近4个季度 | $327.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $123.0M | $-99.8M | ||
| Q3 25 | $78.4M | $-91.4M | ||
| Q2 25 | $72.4M | $-108.3M | ||
| Q1 25 | $55.4M | $-166.5M | ||
| Q4 24 | $84.6M | $-79.3M | ||
| Q3 24 | $-9.0M | $-67.0M | ||
| Q2 24 | $67.4M | $-77.0M | ||
| Q1 24 | $61.9M | $-190.7M |
| Q4 25 | $122.4M | $-100.8M | ||
| Q3 25 | $78.3M | $-92.7M | ||
| Q2 25 | $72.4M | $-110.7M | ||
| Q1 25 | $54.6M | $-167.8M | ||
| Q4 24 | $84.1M | $-79.5M | ||
| Q3 24 | $-9.2M | $-68.6M | ||
| Q2 24 | $67.1M | $-79.0M | ||
| Q1 24 | $61.4M | $-193.9M |
| Q4 25 | 59.6% | -48.6% | ||
| Q3 25 | 37.4% | -58.0% | ||
| Q2 25 | 38.5% | -66.5% | ||
| Q1 25 | 30.7% | -120.5% | ||
| Q4 24 | 46.2% | -48.3% | ||
| Q3 24 | -5.8% | -49.2% | ||
| Q2 24 | 46.2% | -53.7% | ||
| Q1 24 | 42.3% | -178.2% |
| Q4 25 | 0.3% | 0.5% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.4% | 1.0% | ||
| Q4 24 | 0.3% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.2% | 1.4% | ||
| Q1 24 | 0.4% | 3.0% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | — | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COLL
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
